Bionomics IPO Presentation Deck

Pharmacometric Modeling Target Achieved with New Dose Solid Formulation PMX modelling on prior Phase 2 PTSD trial identified liquid suspension under-exposure BNC210 tablet formulation New formulation achieves target AUC >25 mg.hr/L with 900 mg dose bid Pharmacometric (PMX) Analysis Target Exposure RESPONSE (A from Placebo) 10 10 AUC Values (plasma exposure) Bionomics Population phamoxometic modding buid-Administered bakedbly EXPOSURE- RESPONSE CURVE (BASELINE CAPS-5 TOTAL SCORE OF 30) AUC90 25 mg.hr/L EXPOSURE: AUC (mg.hr/L) 7-Day Pharmacokinetic study of BMC2 10 tablet formulationen AUC (mg) standard deviation 7-Day PK Trial New tablet formulation In-clinic setting CAPS-5 Score (PTSD symptoms) 60 BNC210 Novel Spray Dry Dispersion Formulation BNC210 ng/ml 1750- 1500- 1250- 1000- 750- 500- 250- D 01234 300 mg Solid Dose Tablet Fasted High Fat Meal 6 8 10 12 Time (Hr) 18 20 21 Novel tablet overcomes food effect and has dose linear exposure 24

View entire presentation